The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint. With its cash reserves dwindling, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results